technology

Moderna and Merck Achieve Melanoma Breakthrough with mRNA Vaccine

19 Ağustos 2026Bllomberg

A personalized vaccine created by Moderna Inc. and Merck & Co.
has shown promising results in a significant late-stage trial, effectively reducing the recurrence of melanoma. This development raises hopes for improved treatments for the deadliest form of skin cancer and highlights the potential of mRNA technology, which has faced challenges in recent times.
Melanoma is known as the deadliest form of skin cancer, and the development of effective vaccines is critical in improving patient outcomes. The collaboration between Moderna and Merck represents a significant investment in mRNA technology beyond infectious diseases, aiming to harness its potential in cancer treatment.
The success of the personalized vaccine in reducing melanoma recurrence is a pivotal moment for mRNA technology, which has been under scrutiny since its rapid development during the COVID-19 pandemic. This trial not only reinforces the versatility of mRNA platforms but also suggests a shift in how we approach cancer…

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.